Senti Biosciences, Inc. (NASDAQ:SNTI) Sees Large Decline in Short Interest

Senti Biosciences, Inc. (NASDAQ:SNTI) was the recipient of a significant drop in short interest during the month of December. As of December 31st, there was short interest totalling 63,600 shares, a drop of 38.8% from the December 15th total of 103,900 shares. Based on an average trading volume of 2,230,000 shares, the days-to-cover ratio is presently 0.0 days. Currently, 2.2% of the company’s shares are sold short.

Wall Street Analysts Forecast Growth

Separately, Chardan Capital reissued a “buy” rating and issued a $10.00 price target on shares of Senti Biosciences in a research note on Monday, December 2nd.

Senti Biosciences Price Performance

SNTI stock traded down $0.09 on Tuesday, hitting $3.70. 29,176 shares of the company were exchanged, compared to its average volume of 70,171. The stock has a market capitalization of $16.98 million, a price-to-earnings ratio of -0.24 and a beta of 2.42. Senti Biosciences has a twelve month low of $1.52 and a twelve month high of $16.94. The business’s fifty day moving average is $3.83 and its two-hundred day moving average is $2.99.

Senti Biosciences Company Profile

Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.